{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:49:09Z","timestamp":1792014549519,"version":"4.4.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s10157-026-02915-9","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T08:06:23Z","timestamp":1787040383000},"page":"1568-1576","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Renin-related changes after sequential switching from aliskiren to valsartan and sacubitril\/valsartan in patients with a high-renin phenotype: a prospective pilot study"],"prefix":"10.1007","volume":"30","author":[{"given":"Hirofumi","family":"Makino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariko","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Takagaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakazu","family":"Notsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9563-502X","authenticated-orcid":false,"given":"Keizo","family":"Kanasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"key":"2915_CR1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2005.09911.x:S57-65","author":"G Remuzzi","year":"2005","unstructured":"Remuzzi G, Perico N, Macia M, Ruggenenti P. The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease. Kidney Int Suppl. 2005. https:\/\/doi.org\/10.1111\/j.1523-1755.2005.09911.x:S57-65.","journal-title":"Kidney Int Suppl"},{"key":"2915_CR2","doi-asserted-by":"publisher","first-page":"107680","DOI":"10.1016\/j.exer.2019.05.020","volume":"186","author":"KM Mirabito Colafella","year":"2019","unstructured":"Mirabito Colafella KM, Bov\u00e9e DM, Danser AHJ. The renin-angiotensin-aldosterone system and its therapeutic targets. Exp Eye Res. 2019;186:107680.","journal-title":"Exp Eye Res"},{"key":"2915_CR3","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.amjcard.2011.03.034","volume":"108","author":"G Vergaro","year":"2011","unstructured":"Vergaro G, Emdin M, Iervasi A, Zyw L, Gabutti A, Poletti R, et al. Prognostic value of plasma renin activity in heart failure. Am J Cardiol. 2011;108:246\u201351.","journal-title":"Am J Cardiol"},{"key":"2915_CR4","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1093\/eurheartj\/ehr066","volume":"32","author":"S Verma","year":"2011","unstructured":"Verma S, Gupta M, Holmes DT, Xu L, Teoh H, Gupta S, et al. Plasma renin activity predicts cardiovascular mortality in the Heart Outcomes Prevention Evaluation (HOPE) study. Eur Heart J. 2011;32:2135\u201342.","journal-title":"Eur Heart J"},{"key":"2915_CR5","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1001\/jama.1979.03290280031022","volume":"241","author":"JH Laragh","year":"1979","unstructured":"Laragh JH, Letcher RL, Pickering TG. Renin profiling for diagnosis and treatment of hypertension. JAMA. 1979;241:151\u20136.","journal-title":"JAMA"},{"key":"2915_CR6","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1161\/01.HYP.0000253780.36691.4f","volume":"49","author":"E O\u2019Brien","year":"2007","unstructured":"O\u2019Brien E, Barton J, Nussberger J, Mulcahy D, Jensen C, Dicker P, et al. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker. Hypertension. 2007;49:276\u201384.","journal-title":"Hypertension"},{"key":"2915_CR7","first-page":"F798","volume":"250","author":"TJ Opgenorth","year":"1986","unstructured":"Opgenorth TJ, Burnett JC Jr., Granger JP, Scriven TA. Effects of atrial natriuretic peptide on renin secretion in nonfiltering kidney. Am J Physiol. 1986;250:F798\u2013801.","journal-title":"Am J Physiol"},{"key":"2915_CR8","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1186\/s12872-022-02647-0","volume":"22","author":"GB Bolla","year":"2022","unstructured":"Bolla GB, Fedele A, Faggiano A, Sala C, Santangelo G, Carugo S. Effects of sacubitril\/valsartan on biomarkers of fibrosis and inflammation in patients with heart failure with reduced ejection fraction. BMC Cardiovasc Disord. 2022;22:217.","journal-title":"BMC Cardiovasc Disord"},{"key":"2915_CR9","doi-asserted-by":"publisher","first-page":"49","DOI":"10.4070\/kcj.2025.0140","volume":"56","author":"JS Cho","year":"2026","unstructured":"Cho JS, Jung JH, Kwon W, Chung WB, Ihm SH. High plasma renin and aldosterone levels are associated with a unique phenotype in primary hypertension. Korean Circ J. 2026;56:49\u201359.","journal-title":"Korean Circ J"},{"key":"2915_CR10","doi-asserted-by":"publisher","first-page":"711","DOI":"10.2147\/VHRM.S8175","volume":"6","author":"BJ Epstein","year":"2010","unstructured":"Epstein BJ. Aliskiren and valsartan combination therapy for the management of hypertension. Vasc Health Risk Manag. 2010;6:711\u201322.","journal-title":"Vasc Health Risk Manag"},{"key":"2915_CR11","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1373\/clinchem.2008.118000","volume":"55","author":"DJ Campbell","year":"2009","unstructured":"Campbell DJ, Nussberger J, Stowasser M, Danser AH, Morganti A, Frandsen E, et al. Activity assays and immunoassays for plasma Renin and prorenin: information provided and precautions necessary for accurate measurement. Clin Chem. 2009;55:867\u201377.","journal-title":"Clin Chem"},{"key":"2915_CR12","doi-asserted-by":"publisher","first-page":"4769","DOI":"10.1073\/pnas.83.13.4769","volume":"83","author":"A Kurtz","year":"1986","unstructured":"Kurtz A, Della Bruna R, Pfeilschifter J, Taugner R, Bauer C. Atrial natriuretic peptide inhibits renin release from juxtaglomerular cells by a cGMP-mediated process. Proc Natl Acad Sci U S A. 1986;83:4769\u201373.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2915_CR13","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1161\/HYPERTENSIONAHA.116.08484","volume":"69","author":"TD Wang","year":"2017","unstructured":"Wang TD, Tan RS, Lee HY, Ihm SH, Rhee MY, Tomlinson B, et al. Effects of sacubitril\/valsartan (LCZ696) on natriuresis, diuresis, blood pressures, and NT-proBNP in salt-sensitive hypertension. Hypertension. 2017;69:32\u201341.","journal-title":"Hypertension"},{"key":"2915_CR14","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/S0140-6736(09)61966-8","volume":"375","author":"LM Ruilope","year":"2010","unstructured":"Ruilope LM, Dukat A, B\u00f6hm M, Lacourci\u00e8re Y, Gong J, Lefkowitz MP. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet. 2010;375:1255\u201366.","journal-title":"Lancet"},{"key":"2915_CR15","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.jchf.2018.02.004","volume":"6","author":"K Damman","year":"2018","unstructured":"Damman K, Gori M, Claggett B, Jhund PS, Senni M, Lefkowitz MP, et al. Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure. JACC Heart Fail. 2018;6:489\u201398.","journal-title":"JACC Heart Fail"},{"key":"2915_CR16","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","volume":"381","author":"SD Solomon","year":"2019","unstructured":"Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019;381:1609\u201320.","journal-title":"N Engl J Med"},{"key":"2915_CR17","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.echo.2016.01.011","volume":"29","author":"SF Nagueh","year":"2016","unstructured":"Nagueh SF, Smiseth OA, Appleton CP, Byrd BF, Dokainish H, Edvardsen T, et al. Recommendations for the Evaluation of left ventricular diastolic function by echocardiography: an update from the american society of echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2016;29:277\u2013314.","journal-title":"J Am Soc Echocardiogr"},{"key":"2915_CR18","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1001\/jama.2019.12821","volume":"322","author":"JL Januzzi Jr","year":"2019","unstructured":"Januzzi JL Jr., Prescott MF, Butler J, Felker GM, Maisel AS, McCague K, et al. Association of change in N-Terminal Pro-B-Type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction. JAMA. 2019;322:1085\u201395.","journal-title":"JAMA"},{"key":"2915_CR19","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1001\/jamacardio.2023.0065","volume":"8","author":"M Ledwidge","year":"2023","unstructured":"Ledwidge M, Dodd JD, Ryan F, Sweeney C, McDonald K, Fox R, et al. Effect of sacubitril\/valsartan vs valsartan on left atrial volume in patients with pre-heart failure with preserved ejection fraction: the PARABLE randomized clinical trial. JAMA Cardiol. 2023;8:366\u201375.","journal-title":"JAMA Cardiol"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-026-02915-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10157-026-02915-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-026-02915-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:09:43Z","timestamp":1792012183000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10157-026-02915-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":19,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["2915"],"URL":"https:\/\/doi.org\/10.1007\/s10157-026-02915-9","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,18]]},"assertion":[{"value":"31 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have declared that no conflict of interest exists.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee at which the studies were conducted (IRB approval number 20241217-1) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}